Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2003
03/13/2003WO2003021263A1 Use of g protein-coupled receptor protein
03/13/2003WO2003020954A2 205p1b5 in treatment and detection of cancer
03/13/2003WO2003020949A2 Targeted nucleic acid constructs and uses related thereto
03/13/2003WO2003020932A1 Novel secretory proteins and dna thereof
03/13/2003WO2003020911A2 Human schizophrenia gene
03/13/2003WO2003020906A2 Multivalent protein conjugate with multiple ligand-binding domains of receptors
03/13/2003WO2003020901A2 Compositions and methods relating to prostate specific genes and proteins
03/13/2003WO2003020892A2 Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
03/13/2003WO2003020881A2 DOMINANT NEGATIVE VARIANTS OF METHIONINE AMINOPEPTIDASE 2 (MetAP2) AND CLINICAL USES THEREOF
03/13/2003WO2003020876A2 Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
03/13/2003WO2003020769A1 Pemphigus monoclonal antibody
03/13/2003WO2003020766A1 Late gestation lung genes, fragments and uses thereof
03/13/2003WO2003020764A2 Modified factor ix
03/13/2003WO2003020763A2 Soluble t cell receptor
03/13/2003WO2003020761A1 Modified human growth hormone
03/13/2003WO2003020760A1 Modulation of the expression of toll-like receptors influences neurodegeneration and neuroprotection in the human central nervous system
03/13/2003WO2003020759A2 A caspase- 8 binding protein, its preparation and use
03/13/2003WO2003020753A1 Peptidic compounds selectively binding to p-selectin
03/13/2003WO2003020752A1 A peptide and the pharmaceuticals containing it
03/13/2003WO2003020751A2 Homing peptides
03/13/2003WO2003020749A2 Ncam binding compounds
03/13/2003WO2003020748A1 Anti-cancer cyclopenta[g]quinazoline compounds
03/13/2003WO2003020747A1 Modified peptides and their use for the treatment of autoimmune diseases
03/13/2003WO2003020746A1 Modified transferrin fusion proteins
03/13/2003WO2003020702A2 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
03/13/2003WO2003020371A2 Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer
03/13/2003WO2003020325A2 Methods for sterilizing preparations containing albumin
03/13/2003WO2003020324A2 Methods for sterilizing preparations of digestive enzymes
03/13/2003WO2003020321A2 Derivatives of pseudo-peptides, their preparation and their biological uses
03/13/2003WO2003020320A2 Nanoparticles comprising biologically active tnf which is immobilised on the same
03/13/2003WO2003020316A1 Materials sustainedly releasing drug in vivo
03/13/2003WO2003020313A1 Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
03/13/2003WO2003020312A1 Remedy for ischemic heart failure
03/13/2003WO2003020307A1 Bone morphogenic protein 2-induced genes and polypeptides, and their use in diagnostic and therapeutic methods
03/13/2003WO2003020306A1 Desensitizers
03/13/2003WO2003020305A1 Methionine restriction for cancer therapy
03/13/2003WO2003020304A2 Inflammation modulatory compound comprising an endomorphin
03/13/2003WO2003020303A1 Use of leptin for infant with low birth weight for prevention of obesity
03/13/2003WO2003020302A1 Hepatitis b virus proliferation inhibitor
03/13/2003WO2003020301A1 Chromogranin a and fragments thereof for the treatment of diseases involving increased vascular permeability
03/13/2003WO2003020300A1 Use of cyclopenta[g]quinazoline derivatives for treating cancer
03/13/2003WO2003020299A1 L-methionine as a stabilizer for nesp/epo in hsa-free formulations
03/13/2003WO2003020298A1 Optimal compositions and methods thereof for treating hcv infections
03/13/2003WO2003020297A2 Method of improving wound healing
03/13/2003WO2003020262A2 Use of polyunsaturated fatty acids for intra-arterial injection for selectively occluding blood supplies to neoplasias
03/13/2003WO2003020256A1 Use of c2-substituted indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity
03/13/2003WO2003020255A1 Use of polysubstituted indan-1-ol systems for producing drugs used in the prophylaxis or treatment of obesity
03/13/2003WO2003020252A2 Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
03/13/2003WO2003020251A1 Method for enhancing endothelial function in humans
03/13/2003WO2003020245A1 Residual solvent extraction method and microparticles produced thereby
03/13/2003WO2003020227A1 Compositions and methods relating to prevention of chemotherapy-induced alopecia
03/13/2003WO2003020223A2 A cancer treatment system
03/13/2003WO2003020222A2 PYRROLO[2,3-d]PYRIMIDINES FOR INHIBITING RNA-DEPENDENT RNA VIRAL POLYMERASE
03/13/2003WO2003020219A2 Aerosolized decongestants for the treatment of sinusitis
03/13/2003WO2003020215A2 Methods of treating mycocardial event related coditions with thymosin beta 4
03/13/2003WO2003020213A2 Methods and compositions for treating inflammatory disorders
03/13/2003WO2003020212A2 Treatment for central nervous system disorders
03/13/2003WO2003020208A2 Treatment of neurologic hemorrhage
03/13/2003WO2003020205A2 Non-mammalian gnrh analogs and uses thereof in regulation of fertility and pregnancy
03/13/2003WO2003020203A2 Hydrogenated castor oil dispersed in a lipid for pharmaceutically elegant topical ointments
03/13/2003WO2003020201A2 Pre-mixes of glp-1 and basal insulin
03/13/2003WO2003020199A1 Use of derivatives of c2-substituted indan-1-ol systems for producing medicaments for the prophylaxis or the treatment of obesity
03/13/2003WO2003020172A1 An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
03/13/2003WO2003020111A2 Alternatively spliced circulating tissue factor
03/13/2003WO2003020005A2 Lp mammalian proteins; related reagents
03/13/2003WO2003000847A3 Membrane associated progesterone receptor
03/13/2003WO2002099038A3 Adsls as modifiers of the p53 pathway and methods of use
03/13/2003WO2002095006A3 Muscle-specific expression vectors
03/13/2003WO2002089796A3 Methods for selective immunomodulation using pimecrolimus
03/13/2003WO2002085932A3 Constructs and methods for expression of recombinant hcv envelope proteins
03/13/2003WO2002081640A3 Gene shinc-1 and diagnostic and therapeutic uses thereof
03/13/2003WO2002081514A3 A novel f-box protein
03/13/2003WO2002078715A8 Method for induction of an antigen specific anti-inflammatory response
03/13/2003WO2002078606A3 Thrombospondin-2 and uses thereof
03/13/2003WO2002077217A3 Human dual specificity protein phosphatase 7-like protein
03/13/2003WO2002074719A8 Inhibitors of plasmepsins
03/13/2003WO2002074158A3 Two-phase processing of thermosensitive polymers for use as biomaterials
03/13/2003WO2002070693A3 Novel abca6 transporter and uses thereof
03/13/2003WO2002070666A3 Compositions and methods for regulating autolytic processes in bacteria
03/13/2003WO2002068654A3 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
03/13/2003WO2002068015A3 Modular infusion device and method
03/13/2003WO2002067996A3 Beta-endorphin/crf gene therapy for locally combating pain
03/13/2003WO2002067902A3 Modulation of release from dry powder formulations
03/13/2003WO2002067760A3 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
03/13/2003WO2002065986A9 Transporters comprising spaced arginine moieties
03/13/2003WO2002064741A3 Compositions and methods relating to breast specific genes and proteins
03/13/2003WO2002064091A3 Melanocortin metallopeptides for treatment of sexual dysfunction
03/13/2003WO2002062832A3 Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
03/13/2003WO2002060926A3 Hepatitis c tripeptide inhibitors
03/13/2003WO2002060466A3 Gssp3 polynucleotides and polypeptides and uses thereof
03/13/2003WO2002057779A3 Cloning and expression of a new mcp receptor in glial cells
03/13/2003WO2002052270A3 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
03/13/2003WO2002051996A3 Regulation of human cyclophilin-like protein
03/13/2003WO2002050112A3 Isolation of purified tgf- 1 and tgf- 2 from bone tissue
03/13/2003WO2002050102A3 Inhibitors of the e2f-1/cyclin interaction for cancer therapy
03/13/2003WO2002050019A3 Diamines as modulators of chemokine receptor activity
03/13/2003WO2002048363A3 Human transporter proteins, nucleic acid molecules encoding them, and uses thereof
03/13/2003WO2002048336A3 Short peptides from the 'a-region' of protein kinases which selectively modulate protein kinase activity
03/13/2003WO2002047717A3 Targeted enzyme prodrug therapy
03/13/2003WO2002046412A3 Regulation of angiogenesis with zinc finger proteins
1 ... 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 ... 3163